Broncho Munal

Pharmacological properties

broncho-munal® and broncho-munal® n contain a lyophilized bacterial lysate, which most often causes respiratory tract infections, including streptococcus pneumoniae, haemophilus influenzae, klebseiella pneumoniae, klebseiella ozaenae, staphylococcus aureus, streptococcus viridans pyreocrococcus mucisocrococcus viridans pyreocrococcus viridans pyreocrococcus viridans pyrococcus viridans, streptococcus moles, streptococcus moles, streptococcus viridans pyreocrococcus vulpes

Broncho-munal and Broncho-munal^® P stimulate the bodys natural defenses against respiratory tract infections, reducing the frequency, duration and severity of infections of the respiratory tract, as well as reduce the need for antibiotics.

Broncho-munal and Broncho-munal^® P stimulate the cellular and humoral immune response in the mucous membrane of the respiratory tract, as well as other immunocompetent structures of the body. The drug also increases the nonspecific immunity of the body. In preclinical and clinical studies, the following effects of Broncho-munal on the bodys defense mechanisms have been demonstrated:

• the drug stimulates the activity of alveolar macrophages, which secrete cytokines that protect the body from infections;
• the drug increases the number of CD4 T-lymphocytes;
• the drug activates peripheral mononuclear cells that perform a protective function;
• the drug increases the concentration of secretory IgA on the mucous membrane of the respiratory tract and digestive tract;
• Broncho-munal and Broncho-munal^® P stimulate the production of protective adhesive molecules;
• Broncho-munal and Broncho-munal^® P reduces the concentration of IgE antibodies in blood plasma, which can inhibit the development of hypersensitivity reactions.

Pharmacokinetics With oral administration of the drug, a bacterial lysate accumulates in Peyers plaques of the mucous membrane of the digestive tract.

Peyers plaque cells absorb the antigen and present it to subepithelial lymphoid cells, thus inducing a humoral immune response, which leads to increased production of IgA in the mucosa, inhibiting the penetration of microorganisms.

Antigens also stimulate lymphoid cells responsible for cellular defense, which migrate through regional lymph nodes into the thoracic duct, and then into the bloodstream.

With blood flow, they migrate to the mucous membrane of the digestive tract, respiratory tract, as well as the mucous membrane of other organs, where they perform a protective function, increasing the possibility of immune defense.

Indications

Immunotherapy. prevention of recurrent respiratory tract infections and severe infectious exacerbations of chronic bronchitis. concomitant in the treatment of acute respiratory infections.

Children. Broncho Munal^® can be used in children over the age of 12 years, broncho-munal^® P - the drug is not prescribed for children under 6 months of age. Safety and effectiveness of the drug in children under 6 months of age have not been established.

Application

Adults and adolescents over the age of 12 years (for broncho-munal®) and children aged 6 months to 12 years (for broncho-munal® p). preventive therapy / complex therapy: 1 capsule per day on an empty stomach for 10 consecutive days per month, 3 months in a row.

Treatment of exacerbations: 1 capsule per day on an empty stomach until the symptoms disappear (minimum course is 10 days). In the case of concomitant administration with antibiotics, the drug is recommended to be used from the very beginning of treatment.

The interval between courses should be 20 days. If it is necessary to prescribe antibiotics, the drug is recommended to be used simultaneously with antibiotics. Capsules can be opened. If it is difficult for the child to swallow the capsule, its contents can be mixed in the appropriate drink (water, fruit juice, milk).

The drug should be taken in the morning on an empty stomach. If the patient forgot to take the drug, you should take it the next morning.

Contraindications

Hypersensitivity to the active substance or any auxiliary substance that is part of the drug.

Side effects

The reported side effects are classified below according to medra by organ system and frequency: very often (≥1 / 10), often (from ≥1 / 100 to 1/10), infrequently (from ≥1 / 1000 to 1 / 100), rarely (from ≥1 / 10,000 to 1/1000), very rarely (1/10 000), including isolated cases, the frequency is unknown (cannot be estimated from the available data).

From the immune system: infrequently - hypersensitivity reactions (erythematous rashes, generalized rash, erythema, edema, edema of the eyelids, swelling of the face, peripheral edema, swelling, swelling of the face, itching, generalized itching, shortness of breath).

From the nervous system: often - headache.

From the respiratory system, chest and mediastinal organs: often - cough.

From the digestive tract: often - diarrhea, abdominal pain; infrequently - nausea, vomiting.

On the part of the skin and subcutaneous tissues: often - rash; infrequently - urticaria; frequency unknown - angioedema.

General disorders and condition at the injection site: infrequently - increased fatigue; rarely, fever.

In case of prolonged gastrointestinal or respiratory disorders, treatment should be discontinued. With skin reactions, treatment is also interrupted, since these manifestations may be allergic in nature.

special instructions

The drug may cause hypersensitivity reactions. in case of allergic reactions or signs of intolerance to the drug, treatment should be discontinued immediately.

After vaccination with a live vaccine, the drug can be started no earlier than 4 weeks later.

The excipient mannitol can have a mild laxative effect.

The drug contains less than 1 mmol (23 mg) / dose of sodium in the form of sodium glutamate, that is, almost free of sodium.

Use during pregnancy and lactation. There are no clinical data on the use of the drug in pregnant women. Animal experiments have not shown any direct or indirect toxicity affecting pregnancy, embryo development, fetal development, and postnatal development. Regarding breastfeeding, studies have also not been conducted and any data are not available. The drug should be used with caution during pregnancy and lactation.

The ability to influence the reaction rate when driving vehicles or working with mechanisms. Does not affect the ability to drive vehicles and work with mechanisms.

Interactions

The interaction of the drug with other drugs is currently unknown.

Overdose

There were no clear clinical symptoms of an overdose of the drug. no cases of overdose have been reported. in case of overdose, consult a doctor.

Storage conditions

In the original packaging for protection against moisture at a temperature not exceeding 25 ° C.